marketcaparena
Search

    GH

    Guardant Health, Inc.

    Company overview

    Market capitalization
    $23.80B
    Employees
    2,490
    Latest publication
    2026-09-29
    About Guardant Health, Inc.

    Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ4 20232023-12-31 · USDQ4 20162016-12-31 · USD
    Total Revenue334,978,000USD155,054,000USD25,249,000USD
    Cost Of Revenue115,949,000USD-81,135,000USD18,431,000USD
    Gross Profit219,029,000USD236,189,000USD3,125,000USD
    Research Development96,533,000USD89,856,000USD10,859,000USD
    Selling General Administrative61,660,000USD37,665,000USD46,972,000USD
    Selling And Marketing Expenses189,954,000USD79,127,000USD—
    General And Administrative Expenses61,660,000USD——
    Total Operating Expenses348,147,000USD433,700,000USD69,096,000USD
    Operating Income-129,118,000USD-197,511,000USD-43,847,000USD
    Total Other Income Expense Net9,161,000USD9,927,000USD-2,286,000USD
    Interest Income10,199,000USD13,888,000USD—
    Interest Expense1,346,000USD645,000USD3,018,000USD
    Income Before Tax-119,957,000USD-187,584,000USD-46,133,000USD
    Income Tax Expense185,000USD-541,000USD6,000USD
    Net Income-120,142,000USD-187,043,000USD-46,139,000USD
    Net Income Applicable To Common Shares-120,142,000USD—-46,139,000USD
    Unclassified Operating Expenses—227,052,000USD11,265,000USD
    Net Interest Income—13,243,000USD—
    Tax Provision—-541,000USD—
    Net Income From Continuing Ops—-187,043,000USD-46,139,000USD
    Ebit—-186,939,000USD-43,847,000USD
    Ebitda—-176,071,000USD—
    Depreciation And Amortization—10,868,000USD—
    Reconciled Depreciation—10,868,000USD—
    Minority Interest——0USD
    Discontinued Operations——0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets1,912,294,000USD1,915,291,000USD2,013,659,000USD1,276,786,000USD1,331,999,000USD1,344,226,000USD1,485,609,000USD1,538,727,000USD
    Cash And Equivalents1,053,469,000USD———————
    Cash And Short Term Investments1,059,969,000USD1,102,760,000USD1,201,598,000USD580,013,000USD629,143,000USD698,572,000USD839,978,000USD999,069,000USD
    Short Term Investments6,500,000USD113,469,000USD823,395,000USD0USD0USD0USD314,438,000USD310,701,000USD
    Total Current Assets1,364,639,000USD1,367,505,000USD1,466,046,000USD828,885,000USD883,432,000USD927,026,000USD1,055,114,000USD1,226,715,000USD
    Other Current Assets61,458,000USD43,490,000USD40,723,000USD42,798,000USD39,976,000USD35,772,000USD33,800,000USD66,883,000USD
    Other Non Current Assets27,996,000USD———————
    Total Liabilities2,135,161,000USD———————
    Total Current Liabilities338,962,000USD292,145,000USD302,730,000USD236,919,000USD238,430,000USD225,753,000USD225,583,000USD197,345,000USD
    Other Current Liabilities79,291,000USD———————
    Other Non Current Liabilities126,944,000USD———————
    Total Stockholder Equity-222,867,000USD-181,073,000USD-99,307,000USD-354,473,000USD-305,475,000USD-250,789,000USD-139,647,000USD-60,096,000USD
    Total Equity Including Noncontrolling Interest-222,867,000USD———————
    Deferred Revenue44,791,000USD———————
    Deferred Revenue Non Current7,200,000USD———————
    Net Receivables144,249,000USD137,404,000USD137,849,000USD115,585,000USD130,252,000USD115,426,000USD110,253,000USD88,465,000USD
    Inventory105,463,000USD83,851,000USD85,876,000USD90,489,000USD84,061,000USD77,256,000USD71,083,000USD72,298,000USD
    Property Plant Equipment Net302,865,000USD303,941,000USD304,764,000USD288,159,000USD295,909,000USD269,794,000USD279,078,000USD270,133,000USD
    Goodwill77,257,000USD———————
    Intangible Assets25,267,000USD25,543,000USD25,921,000USD5,477,000USD5,864,000USD6,280,000USD6,760,000USD7,251,000USD
    Accounts Payable93,514,000USD75,034,000USD54,442,000USD20,142,000USD44,802,000USD49,770,000USD38,551,000USD15,473,000USD
    Short Term Debt27,758,000USD28,030,000USD27,679,000USD26,395,000USD26,277,000USD29,666,000USD29,213,000USD27,383,000USD
    Retained Earnings-3,226,729,000USD-3,106,587,000USD-2,994,512,000USD-2,866,018,000USD-2,773,293,000USD-2,673,394,000USD-2,578,235,000USD-2,467,229,000USD
    Accumulated Other Comprehensive Income-5,563,000USD-5,152,000USD-4,852,000USD-4,260,000USD-3,723,000USD-4,658,000USD-5,201,000USD-3,284,000USD
    Total Liab—2,096,364,000USD2,112,966,000USD1,631,259,000USD1,637,474,000USD1,595,015,000USD1,625,256,000USD1,598,823,000USD
    Other Current Liab—141,309,000USD169,856,000USD143,521,000USD112,996,000USD110,015,000USD122,351,000USD124,935,000USD
    Common Stock—1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Capital Stock—1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Good Will—77,257,000USD77,257,000USD3,290,000USD3,290,000USD3,290,000USD3,290,000USD3,290,000USD
    Cash—989,291,000USD378,203,000USD580,013,000USD629,143,000USD698,572,000USD525,540,000USD688,368,000USD
    Current Deferred Revenue—47,772,000USD50,753,000USD46,861,000USD54,355,000USD36,302,000USD35,468,000USD29,554,000USD
    Net Debt—715,265,000USD1,331,939,000USD746,363,000USD705,008,000USD607,811,000USD810,512,000USD651,047,000USD
    Short Long Term Debt Total—1,704,556,000USD1,710,142,000USD1,326,376,000USD1,334,151,000USD1,306,383,000USD1,336,052,000USD1,339,415,000USD
    Long Term Debt—1,503,471,000USD1,504,000,000USD1,114,594,000USD1,115,526,000USD1,116,339,000USD1,142,547,000USD1,141,901,000USD
    Property Plant Equipment Gross—508,940,000USD503,665,000USD479,477,000USD480,846,000USD445,077,000USD444,603,000USD427,053,000USD
    Common Stock Shares Outstanding—131,273,000shares128,657,000shares125,304,000shares124,114,000shares123,871,000shares123,754,000shares123,051,000shares
    Non Current Assets Total—547,786,000USD547,613,000USD447,901,000USD448,567,000USD417,200,000USD430,495,000USD312,012,000USD
    Non Current Liabilities Total—1,804,219,000USD1,810,236,000USD1,394,340,000USD1,399,044,000USD1,369,262,000USD1,399,673,000USD1,401,478,000USD
    Non Current Liabilities Other—127,693,000USD127,773,000USD94,359,000USD91,170,000USD92,545,000USD92,834,000USD89,446,000USD
    Non Currrent Assets Other—141,045,000USD139,671,000USD21,373,000USD21,067,000USD21,455,000USD141,367,000USD31,338,000USD
    Net Working Capital—1,075,360,000USD1,163,316,000USD591,966,000USD645,002,000USD701,273,000USD829,531,000USD1,029,370,000USD
    Unclassified Non Current Liabilities—173,055,000USD178,463,000USD185,387,000USD192,348,000USD160,378,000USD164,292,000USD170,131,000USD
    Unclassified Equity—2,930,664,000USD2,900,055,000USD2,515,803,000USD2,471,539,000USD2,427,261,000USD2,443,787,000USD2,410,415,000USD
    Unclassified Non Current Assets———129,602,000USD122,437,000USD116,381,000USD——
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets2,013,659,000USD1,485,609,000USD1,786,421,000USD1,609,985,000USD2,204,499,000USD2,271,781,000USD962,535,000USD587,403,000USD
    Intangible Assets25,921,000USD6,760,000USD8,979,000USD11,727,000USD14,207,000USD16,155,000USD15,414,000USD7,800,000USD
    Other Current Assets40,723,000USD33,800,000USD27,741,000USD31,509,000USD53,052,000USD17,466,000USD11,389,000USD5,204,000USD
    Total Liab2,112,966,000USD1,625,256,000USD1,627,737,000USD1,549,805,000USD1,559,494,000USD916,186,000USD114,542,000USD62,451,000USD
    Total Stockholder Equity-99,307,000USD-139,647,000USD158,684,000USD60,180,000USD645,005,000USD1,298,495,000USD798,393,000USD483,152,000USD
    Other Current Liab169,856,000USD122,351,000USD108,261,000USD85,028,000USD127,765,000USD39,653,000USD34,070,000USD18,694,000USD
    Common Stock1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Capital Stock1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Retained Earnings-2,994,512,000USD-2,578,235,000USD-2,141,862,000USD-1,662,413,000USD-1,007,825,000USD-606,592,000USD-352,809,000USD-280,799,000USD
    Good Will77,257,000USD3,290,000USD3,290,000USD3,290,000USD3,290,000USD3,290,000USD3,290,000USD—
    Cash378,203,000USD525,540,000USD1,133,537,000USD141,647,000USD492,202,000USD832,977,000USD143,228,000USD140,544,000USD
    Cash And Short Term Investments1,201,598,000USD839,978,000USD1,168,634,000USD1,011,231,000USD932,748,000USD1,794,880,000USD522,802,000USD418,961,000USD
    Total Current Assets1,466,046,000USD1,055,114,000USD1,347,106,000USD1,191,594,000USD1,114,126,000USD1,888,361,000USD597,358,000USD468,991,000USD
    Total Current Liabilities302,730,000USD225,583,000USD205,917,000USD193,220,000USD194,687,000USD66,809,000USD72,734,000USD46,944,000USD
    Current Deferred Revenue50,753,000USD35,468,000USD17,965,000USD17,403,000USD11,326,000USD8,550,000USD12,277,000USD16,138,000USD
    Net Debt1,331,939,000USD810,512,000USD220,227,000USD1,227,637,000USD881,528,000USD21,512,000USD-102,832,000USD-140,544,000USD
    Short Term Debt27,679,000USD29,213,000USD27,950,000USD21,878,000USD12,856,000USD6,632,000USD7,140,000USD97,000USD
    Short Long Term Debt Total1,710,142,000USD1,336,052,000USD1,353,764,000USD1,369,284,000USD1,373,730,000USD854,489,000USD40,396,000USD216,000USD
    Long Term Debt1,504,000,000USD1,142,547,000USD1,139,966,000USD1,137,391,000USD1,134,821,000USD806,292,000USD——
    Short Term Investments823,395,000USD314,438,000USD35,097,000USD869,584,000USD440,546,000USD961,903,000USD379,574,000USD278,417,000USD
    Net Receivables137,849,000USD110,253,000USD88,783,000USD97,256,000USD97,652,000USD53,299,000USD47,986,000USD35,690,000USD
    Inventory85,876,000USD71,083,000USD61,948,000USD51,598,000USD30,674,000USD22,716,000USD15,181,000USD9,136,000USD
    Accounts Payable54,442,000USD38,551,000USD51,741,000USD68,911,000USD38,517,000USD7,340,000USD16,197,000USD10,642,000USD
    Property Plant Equipment Net304,764,000USD279,078,000USD302,712,000USD341,921,000USD313,904,000USD100,125,000USD72,808,000USD31,003,000USD
    Property Plant Equipment Gross503,665,000USD444,603,000USD430,020,000USD341,921,000USD313,904,000USD100,125,000USD72,808,000USD31,003,000USD
    Accumulated Other Comprehensive Income-4,852,000USD-5,201,000USD-3,675,000USD-19,522,000USD-4,764,000USD2,697,000USD1,111,000USD-83,000USD
    Common Stock Shares Outstanding125,374,000shares122,745,000shares111,988,000shares102,178,000shares101,314,000shares97,504,000shares90,597,000shares85,029,000shares
    Non Current Assets Total547,613,000USD430,495,000USD439,315,000USD418,391,000USD1,090,373,000USD383,420,000USD365,177,000USD118,412,000USD
    Non Current Liabilities Total1,810,236,000USD1,399,673,000USD1,421,820,000USD1,356,585,000USD1,364,807,000USD849,377,000USD41,808,000USD15,507,000USD
    Non Current Liabilities Other127,773,000USD92,834,000USD96,006,000USD9,179,000USD3,933,000USD43,085,000USD8,552,000USD7,544,000USD
    Non Currrent Assets Other139,671,000USD141,367,000USD124,334,000USD61,453,000USD60,938,000USD17,253,000USD4,882,000USD2,046,000USD
    Net Working Capital1,163,316,000USD829,531,000USD1,141,189,000USD998,374,000USD919,439,000USD1,821,552,000USD524,624,000USD422,047,000USD
    Unclassified Non Current Liabilities178,463,000USD164,292,000USD185,848,000USD200,836,000USD222,120,000USD—24,704,000USD-15,388,000USD
    Unclassified Equity2,900,055,000USD2,443,787,000USD2,304,219,000USD1,742,113,000USD1,657,592,000USD1,902,388,000USD1,150,089,000USD764,032,000USD
    Other Liab———9,179,000USD3,933,000USD1,520,000USD8,552,000USD15,507,000USD
    Other Assets———36,453,000USD60,938,000USD17,208,000USD4,882,000USD2,046,000USD
    Long Term Investments———0USD698,034,000USD246,597,000USD268,783,000USD77,563,000USD
    Net Tangible Assets———45,163,000USD627,508,000USD1,336,150,000USD779,689,000USD475,352,000USD
    Unclassified Non Current Assets———-36,453,000USD-60,938,000USD-17,208,000USD-4,882,000USD-2,046,000USD
    Unclassified Current Liabilities————4,223,000USD4,634,000USD3,050,000USD1,373,000USD
    Deferred Long Term Liab———————7,844,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation19,003,000USD
    Stock Based Compensation105,333,000USD
    Other Non Cash Items219,000USD
    Change To Account Receivables-5,944,000USD
    Change To Inventory-19,587,000USD
    Change In Working Capital-47,764,000USD
    Operating Cash Flow-123,401,000USD
    Capital Expenditures-17,339,000USD
    Net Investments818,230,000USD
    Investing Cash Flow800,891,000USD
    Common Stock Issuance10,362,000USD
    Net Common Stock Issuance-28,969,000USD
    Other Financing Activities-1,431,000USD
    Unclassified Financing Cash Flow21,475,000USD
    Financing Cash Flow1,437,000USD
    Effect Of Forex Changes On Cash-605,000USD
    Change In Cash678,322,000USD
    End Cash Flow1,167,739,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-112,075,000USD-128,494,000USD-92,725,000USD-99,899,000USD-95,159,000USD-111,006,000USD-107,754,000USD-102,628,000USD
    Depreciation9,442,000USD10,050,000USD9,408,000USD10,042,000USD10,236,000USD10,454,000USD10,598,000USD10,623,000USD
    Stock Based Compensation47,608,000USD43,190,000USD42,808,000USD42,462,000USD37,757,000USD36,366,000USD49,769,000USD27,235,000USD
    Other Non Cash Items12,673,000USD72,069,000USD8,236,000USD7,352,000USD7,815,000USD2,505,000USD8,527,000USD24,466,000USD
    Change To Account Receivables942,000USD-22,204,000USD14,454,000USD-14,310,000USD-6,115,000USD-21,705,000USD12,053,000USD-15,957,000USD
    Change To Inventory2,025,000USD4,614,000USD-6,428,000USD-6,805,000USD-6,173,000USD1,214,000USD-5,314,000USD-3,993,000USD
    Change In Working Capital-23,271,000USD32,290,999USD-3,140,000USD-20,242,000USD-23,338,000USD-2,832,000USD-12,199,000USD-53,698,000USD
    Total Cash From Operating Activities-65,623,000USD-14,084,000USD-35,413,000USD-60,285,000USD-62,689,000USD-64,513,000USD-51,059,000USD-94,002,000USD
    Capital Expenditures-5,580,000USD-27,848,000USD-10,350,000USD-5,649,000USD-4,459,000USD-18,875,000USD-4,199,000USD-5,077,000USD
    Free Cash Flow-71,203,000USD-41,932,000USD-45,763,000USD-65,934,000USD-67,148,000USD-83,388,000USD-55,258,000USD-99,079,000USD
    Investments704,998,000USD-818,231,000USD-14,350,000USD-10,649,000USD302,864,000USD10,530,000USD-294,827,000USD-5,077,000USD
    Total Cashflows From Investing Activities699,418,000USD-905,067,000USD-14,350,000USD-10,649,000USD302,864,000USD10,530,000USD-294,827,000USD-5,077,000USD
    Net Borrowings0USD397,470,000USD44,000USD-44,000USD5,030,000USD———
    Total Cash From Financing Activities-21,577,000USD719,739,000USD4,331,000USD1,624,000USD-66,850,000USD-2,935,000USD-2,885,000USD5,898,000USD
    Sale Purchase Of Stock0USD0USD52,690,000USD7,680,000USD-45,010,000USD—1,544,000USD7,212,000USD
    Change In Cash612,024,000USD-201,810,000USD-45,965,000USD-68,373,000USD174,098,000USD-58,613,000USD-346,871,000USD-94,018,000USD
    Begin Period Cash Flow489,417,000USD580,013,000USD735,480,000USD803,853,000USD629,755,000USD688,368,000USD1,035,239,000USD1,129,257,000USD
    End Period Cash Flow1,101,441,000USD378,203,000USD689,515,000USD735,480,000USD803,853,000USD629,755,000USD688,368,000USD1,035,239,000USD
    Other Cashflows From Investing Activities954,934,000USD—5,000,000USD-5,000,000USD————
    Other Cashflows From Financing Activities-25,228,000USD-4,587,000USD610,000USD-7,569,000USD-26,870,000USD-2,935,000USD-2,885,000USD6,079,000USD
    Unclassified Investing Cash Flow-954,934,000USD-58,988,000USD5,350,000USD10,649,000USD4,459,000USD18,875,000USD4,199,000USD5,077,000USD
    Unclassified Financing Cash Flow3,651,000USD326,856,000USD-49,013,000USD1,557,000USD——-1,544,000USD-7,393,000USD
    Unclassified Operating Cash Flow—-43,189,999USD——————
    Issuance Of Capital Stock—————0USD0USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-416,277,000USD-436,373,000USD-479,449,000USD-654,588,000USD-384,770,000USD-246,283,000USD-67,851,000USD-84,263,000USD
    Depreciation39,736,000USD42,387,000USD42,881,000USD35,962,000USD22,271,000USD16,065,000USD11,411,000USD7,136,000USD
    Stock Based Compensation166,217,000USD140,411,000USD90,759,000USD94,685,000USD151,449,000USD144,113,000USD16,954,000USD6,851,000USD
    Other Non Cash Items15,782,000USD74,579,000USD-33,006,000USD152,914,000USD42,501,000USD18,676,000USD2,252,000USD-782,000USD
    Change To Account Receivables-28,175,000USD-21,389,000USD8,378,000USD375,000USD-44,353,000USD-5,463,000USD-7,389,000USD-22,903,000USD
    Change To Inventory-14,792,000USD-9,135,000USD-10,350,000USD-20,926,000USD-7,957,000USD-7,535,000USD-6,045,000USD-1,849,000USD
    Change In Working Capital9,782,000USD-60,862,000USD53,840,000USD61,564,000USD-40,468,000USD-47,665,000USD-8,303,000USD-1,127,000USD
    Total Cash From Operating Activities-184,760,000USD-239,858,000USD-324,975,000USD-309,463,000USD-209,017,000USD-103,927,000USD-47,134,000USD-72,185,000USD
    Capital Expenditures-48,306,000USD-35,085,000USD-20,486,000USD-77,461,000USD-75,035,000USD-54,059,000USD-21,285,000USD-20,203,000USD
    Free Cash Flow-233,066,000USD-274,943,000USD-345,461,000USD-386,924,000USD-284,052,000USD-157,986,000USD-68,419,000USD-92,388,000USD
    Investments-519,908,000USD-261,308,000USD247,423,000USD149,816,000USD51,302,000USD-563,027,000USD-288,957,000USD-132,825,000USD
    Total Cashflows From Investing Activities-627,202,000USD-261,308,000USD840,250,000USD149,816,000USD-63,155,000USD-617,086,000USD-317,570,000USD-153,028,000USD
    Net Borrowings402,500,000USD0USD0USD-71,000USD-784,000USD1,042,705,000USD-128,000USD-443,000USD
    Total Cash From Financing Activities671,133,000USD-996,000USD477,375,000USD-189,093,000USD-66,824,000USD1,410,307,000USD367,304,000USD293,161,000USD
    Sale Purchase Of Stock13,585,000USD11,719,000USD10,154,000USD-7,878,000USD-83,759,000USD7,095,000USD-723,000USD-172,000USD
    Issuance Of Capital Stock345,000,000USD0USD493,116,000USD0USD0USD355,730,000USD350,432,000USD254,006,000USD
    Change In Cash-140,338,000USD-503,932,000USD991,739,000USD-350,340,000USD-340,689,000USD689,749,000USD2,684,000USD67,948,000USD
    Begin Period Cash Flow629,755,000USD1,133,687,000USD141,948,000USD492,288,000USD832,977,000USD143,228,000USD140,544,000USD72,596,000USD
    End Period Cash Flow489,417,000USD629,755,000USD1,133,687,000USD141,948,000USD492,288,000USD832,977,000USD143,228,000USD140,544,000USD
    Other Cashflows From Financing Activities569,676,000USD-15,834,000USD-15,741,000USD-189,022,000USD-66,678,000USD1,054,751,000USD17,310,000USD39,770,000USD
    Unclassified Investing Cash Flow-58,988,000USD35,085,000USD611,782,000USD-149,816,000USD-51,302,000USD17,886,000USD-4,760,000USD132,825,000USD
    Unclassified Financing Cash Flow-314,628,000USD3,119,000USD482,962,000USD7,878,000USD102,262,000USD-687,149,000USD350,845,000USD257,162,000USD
    Other Cashflows From Investing Activities——1,531,000USD227,277,000USD11,880,000USD-17,886,000USD-2,568,000USD-132,825,000USD
    Change To Liabilities———9,873,000USD37,572,000USD-3,222,000USD15,340,000USD26,432,000USD
    Cash And Cash Equivalents Changes———-348,740,000USD-338,996,000USD689,294,000USD2,600,000USD67,948,000USD
    Dividends Paid————-17,865,000USD-7,095,000USD—-3,156,000USD
    Unclassified Operating Cash Flow—————11,167,000USD-1,597,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyInternational16,940,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States318,038,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductBiopharma Data60,947,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductLicensing Other2,060,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOncology219,105,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductScreening52,866,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyInternational17,036,000USD0001576280-26-000026
    Q1 2026Quarterly · 2026-03-31GeographyUnited States284,629,000USD0001576280-26-000026
    Q1 2026Quarterly · 2026-03-31ProductBiopharma Data52,977,000USD0001576280-26-000026
    Q1 2026Quarterly · 2026-03-31ProductLicensing Other2,144,000USD0001576280-26-000026
    Q1 2026Quarterly · 2026-03-31ProductOncology204,954,000USD0001576280-26-000026
    Q1 2026Quarterly · 2026-03-31ProductScreening41,590,000USD0001576280-26-000026
    Q4 2025Quarterly · 2025-12-31GeographyInternational17,720,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States263,546,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductBiopharma Data54,005,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductLicensing Other2,183,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOncology189,949,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductScreening35,129,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational58,742,000USD0001576280-26-000013
    FY 2025Yearly · 2025-12-31GeographyUnited States923,279,000USD0001576280-26-000013
    FY 2025Yearly · 2025-12-31ProductBiopharma Data210,132,000USD0001576280-26-000013
    FY 2025Yearly · 2025-12-31ProductLicensing Other8,562,000USD0001576280-26-000013
    FY 2025Yearly · 2025-12-31ProductOncology683,595,000USD0001576280-26-000013
    FY 2025Yearly · 2025-12-31ProductScreening79,732,000USD0001576280-26-000013
    Q3 2025Quarterly · 2025-09-30GeographyInternational15,756,000USD0001576280-25-000277
    Q3 2025Quarterly · 2025-09-30GeographyUnited States249,440,000USD0001576280-25-000277
    Q3 2025Quarterly · 2025-09-30ProductBiopharma Data54,731,000USD0001576280-25-000277
    Q3 2025Quarterly · 2025-09-30ProductLicensing Other1,951,000USD0001576280-25-000277
    Q3 2025Quarterly · 2025-09-30ProductOncology184,402,000USD0001576280-25-000277
    Q3 2025Quarterly · 2025-09-30ProductScreening24,112,000USD0001576280-25-000277
    Q2 2025Quarterly · 2025-06-30GeographyInternational15,404,000USD0001576280-25-000246
    Q2 2025Quarterly · 2025-06-30GeographyUnited States216,684,000USD0001576280-25-000246
    Q2 2025Quarterly · 2025-06-30ProductBiopharma Data56,020,000USD0001576280-25-000246
    Q2 2025Quarterly · 2025-06-30ProductLicensing Other2,569,000USD0001576280-25-000246
    Q2 2025Quarterly · 2025-06-30ProductOncology158,685,000USD0001576280-25-000246
    Q2 2025Quarterly · 2025-06-30ProductScreening14,814,000USD0001576280-25-000246
    Q1 2025Quarterly · 2025-03-31GeographyInternational9,862,000USD0001576280-26-000026
    Q1 2025Quarterly · 2025-03-31GeographyUnited States193,609,000USD0001576280-26-000026
    Q1 2025Quarterly · 2025-03-31ProductBiopharma Data45,376,000USD0001576280-26-000026
    Q1 2025Quarterly · 2025-03-31ProductLicensing Other1,859,000USD0001576280-26-000026
    Q1 2025Quarterly · 2025-03-31ProductOncology150,559,000USD0001576280-26-000026
    Q1 2025Quarterly · 2025-03-31ProductScreening5,677,000USD0001576280-26-000026
    Q4 2024Quarterly · 2024-12-31GeographyInternational10,220,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States191,594,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductBiopharma Data49,512,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductLicensing Other2,568,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOncology145,613,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductScreening4,121,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational41,854,000USD0001576280-26-000013
    FY 2024Yearly · 2024-12-31GeographyUnited States697,162,000USD0001576280-26-000013
    FY 2024Yearly · 2024-12-31ProductBiopharma Data177,579,000USD0001576280-26-000013
    FY 2024Yearly · 2024-12-31ProductLicensing Other13,486,000USD0001576280-26-000013
    FY 2024Yearly · 2024-12-31ProductOncology542,827,000USD0001576280-26-000013
    FY 2024Yearly · 2024-12-31ProductScreening5,124,000USD0001576280-26-000013
    Q3 2024Quarterly · 2024-09-30GeographyInternational11,371,000USD0001576280-25-000277
    Q3 2024Quarterly · 2024-09-30GeographyUnited States180,105,000USD0001576280-25-000277
    Q3 2024Quarterly · 2024-09-30ProductBiopharma Data46,547,000USD0001576280-25-000277
    Q3 2024Quarterly · 2024-09-30ProductLicensing Other2,729,000USD0001576280-25-000277
    Q3 2024Quarterly · 2024-09-30ProductOncology141,197,000USD0001576280-25-000277
    Q3 2024Quarterly · 2024-09-30ProductScreening1,003,000USD0001576280-25-000277
    FY 2023Yearly · 2023-12-31GeographyInternational37,424,000USD0001576280-26-000013
    FY 2023Yearly · 2023-12-31GeographyUnited States526,524,000USD0001576280-26-000013
    FY 2023Yearly · 2023-12-31ProductBiopharma Data136,351,000USD0001576280-26-000013
    FY 2023Yearly · 2023-12-31ProductLicensing Other23,721,000USD0001576280-26-000013
    FY 2023Yearly · 2023-12-31ProductOncology403,876,000USD0001576280-26-000013
    FY 2023Yearly · 2023-12-31ProductScreening0USD0001576280-26-000013
    FY 2022Yearly · 2022-12-31GeographyInternational28,920,000USD0001576280-25-000044
    FY 2022Yearly · 2022-12-31GeographyUnited States420,618,000USD0001576280-25-000044
    FY 2021Yearly · 2021-12-31GeographyInternational21,092,000USD0001576280-24-000043
    FY 2021Yearly · 2021-12-31GeographyUnited States352,561,000USD0001576280-24-000043
    FY 2020Yearly · 2020-12-31GeographyInternational22,073,000USD0001576280-23-000020
    FY 2020Yearly · 2020-12-31GeographyUnited States264,657,000USD0001576280-23-000020
    FY 2019Yearly · 2019-12-31GeographyInternational20,063,000USD0001576280-22-000015
    FY 2019Yearly · 2019-12-31GeographyUnited States194,312,000USD0001576280-22-000015
    FY 2018Yearly · 2018-12-31GeographyInternational12,723,000USD0001576280-21-000031
    FY 2018Yearly · 2018-12-31GeographyUnited States77,916,000USD0001576280-21-000031

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.